NCT05579431View on ClinicalTrials.gov

A Phase 1, First-in-human Study of VX-634

PHASE1CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

May 24, 2023

Study Completion Date

November 13, 2023

Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
DRUG

VX-634

Suspension for oral administration.

DRUG

Placebo

Suspension for oral administration.

Trial Locations (5)

32610

University of Florida, Gainesville

32803

Central Florida Pulmonary Group, P.A., Orlando

66219

ICON Lenexa, Lenexa

84124

ICON Salt Lake City, Salt Lake City

85283

Celerion - Tempe, Tempe

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY